このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Pliant Therapeutics マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Bernard Coulie
最高経営責任者
US$11.2m
報酬総額
| CEO給与比率 | 5.5% |
| CEO在任期間 | 8.6yrs |
| CEOの所有権 | 1.1% |
| 経営陣の平均在職期間 | 8.5yrs |
| 取締役会の平均在任期間 | 6.9yrs |
経営陣の近況
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings
Jan 21
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$185m |
| Mar 31 2024 | n/a | n/a | -US$171m |
| Dec 31 2023 | US$11m | US$610k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$11m | US$587k | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$5m | US$556k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$499k | -US$42m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$19m |
| Mar 31 2020 | n/a | n/a | US$20m |
| Dec 31 2019 | US$2m | US$428k | -US$7m |
報酬と市場: Bernardの 総報酬 ($USD 11.17M ) は、 US市場 ($USD 3.30M ) の同規模の企業の平均を上回っています。
報酬と収益: Bernardの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Bernard Coulie (57 yo)
8.6yrs
在職期間
US$11,165,999
報酬
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | no data | US$11.17m | 1.1% $ 7.4m | |
| Chief Financial Officer | 5.8yrs | US$4.44m | 0.31% $ 2.1m | |
| General Counsel & Corporate Secretary | 3.9yrs | US$3.32m | 0.060% $ 408.2k | |
| Chief Business Officer | 8.5yrs | US$4.36m | 0.32% $ 2.1m | |
| Chief Medical Officer | 6.3yrs | US$4.69m | 0.22% $ 1.5m | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | データなし | データなし | |
| Interim Chief Technology Officer | no data | データなし | データなし | |
| Vice President of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| Chief Human Resources Officer | 1.7yrs | データなし | 0.0013% $ 8.9k |
8.5yrs
平均在職期間
51yo
平均年齢
経験豊富な経営陣: PLRXの経営陣は経験豊富で経験豊富です（平均在職期間は8.4年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 8.6yrs | US$11.17m | 1.1% $ 7.4m | |
| Scientific Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Scientific Founder & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.8yrs | US$278.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 8.2yrs | US$277.21k | 0.058% $ 391.9k | |
| Independent Director | 7.1yrs | US$271.96k | 0.048% $ 327.0k | |
| Independent Chairman | 6.8yrs | US$296.71k | 0.16% $ 1.1m | |
| Independent Director | 5.5yrs | US$277.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし |
6.9yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: PLRXの 取締役会 は 経験豊富 であると考えられます ( 6.8年の平均在任期間)。